Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Möhrle JJ[au]:

Search results

Items: 29

1.

DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum.

Collins KA, Rückle T, Elliott S, Marquart L, Ballard E, Chalon S, Griffin P, Möhrle JJ, McCarthy JS.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01837-18. doi: 10.1128/AAC.01837-18. Print 2019 Apr.

2.

Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria.

Macintyre F, Ramachandruni H, Burrows JN, Holm R, Thomas A, Möhrle JJ, Duparc S, Hooft van Huijsduijnen R, Greenwood B, Gutteridge WE, Wells TNC, Kaszubska W.

Malar J. 2018 Nov 1;17(1):402. doi: 10.1186/s12936-018-2549-1. Review.

3.

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.

Llanos-Cuentas A, Casapia M, Chuquiyauri R, Hinojosa JC, Kerr N, Rosario M, Toovey S, Arch RH, Phillips MA, Rozenberg FD, Bath J, Ng CL, Cowell AN, Winzeler EA, Fidock DA, Baker M, Möhrle JJ, Hooft van Huijsduijnen R, Gobeau N, Araeipour N, Andenmatten N, Rückle T, Duparc S.

Lancet Infect Dis. 2018 Aug;18(8):874-883. doi: 10.1016/S1473-3099(18)30309-8. Epub 2018 Jun 13. Erratum in: Lancet Infect Dis. 2018 Aug;18(8):829.

4.

A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.

Collins KA, Wang CY, Adams M, Mitchell H, Rampton M, Elliott S, Reuling IJ, Bousema T, Sauerwein R, Chalon S, Möhrle JJ, McCarthy JS.

J Clin Invest. 2018 Apr 2;128(4):1551-1562. doi: 10.1172/JCI98012. Epub 2018 Mar 12.

5.

A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation.

Murphy SC, Duke ER, Shipman KJ, Jensen RL, Fong Y, Ferguson S, Janes HE, Gillespie K, Seilie AM, Hanron AE, Rinn L, Fishbaugher M, VonGoedert T, Fritzen E, Kappe SH, Chang M, Sousa JC, Marcsisin SR, Chalon S, Duparc S, Kerr N, Möhrle JJ, Andenmatten N, Rueckle T, Kublin JG.

J Infect Dis. 2018 Feb 14;217(5):693-702. doi: 10.1093/infdis/jix613. Erratum in: J Infect Dis. 2018 Jul 2;218(3):508.

6.

Model-Informed Drug Development for Malaria Therapeutics.

Andrews KA, Wesche D, McCarthy J, Möhrle JJ, Tarning J, Phillips L, Kern S, Grasela T.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:567-582. doi: 10.1146/annurev-pharmtox-010715-103429. Epub 2017 Oct 6. Review.

PMID:
28992431
7.

Treating malaria: new drugs for a new era.

Shanks GD, Möhrle JJ.

Lancet Infect Dis. 2017 Dec;17(12):1223-1224. doi: 10.1016/S1473-3099(17)30475-9. Epub 2017 Sep 12. No abstract available.

8.

Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers.

Rueangweerayut R, Bancone G, Harrell EJ, Beelen AP, Kongpatanakul S, Möhrle JJ, Rousell V, Mohamed K, Qureshi A, Narayan S, Yubon N, Miller A, Nosten FH, Luzzatto L, Duparc S, Kleim JP, Green JA.

Am J Trop Med Hyg. 2017 Sep;97(3):702-711. doi: 10.4269/ajtmh.16-0779. Epub 2017 Jul 27.

9.

Erratum to: New developments in anti-malarial target candidate and product profiles.

Burrows JN, Duparc S, Gutteridge WE, van Huijsduijnen RH, Kaszubska W, Macintyre F, Mazzuri S, Möhrle JJ, Wells TNC.

Malar J. 2017 Apr 18;16(1):151. doi: 10.1186/s12936-017-1809-9. No abstract available.

10.

DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.

Sulyok M, Rückle T, Roth A, Mürbeth RE, Chalon S, Kerr N, Samec SS, Gobeau N, Calle CL, Ibáñez J, Sulyok Z, Held J, Gebru T, Granados P, Brückner S, Nguetse C, Mengue J, Lalremruata A, Sim BKL, Hoffman SL, Möhrle JJ, Kremsner PG, Mordmüller B.

Lancet Infect Dis. 2017 Jun;17(6):636-644. doi: 10.1016/S1473-3099(17)30139-1. Epub 2017 Mar 28. Erratum in: Lancet Infect Dis. 2017 Jun;17(6):576.

11.

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.

McCarthy JS, Lotharius J, Rückle T, Chalon S, Phillips MA, Elliott S, Sekuloski S, Griffin P, Ng CL, Fidock DA, Marquart L, Williams NS, Gobeau N, Bebrevska L, Rosario M, Marsh K, Möhrle JJ.

Lancet Infect Dis. 2017 Jun;17(6):626-635. doi: 10.1016/S1473-3099(17)30171-8. Epub 2017 Mar 28.

12.

New developments in anti-malarial target candidate and product profiles.

Burrows JN, Duparc S, Gutteridge WE, Hooft van Huijsduijnen R, Kaszubska W, Macintyre F, Mazzuri S, Möhrle JJ, Wells TNC.

Malar J. 2017 Jan 13;16(1):26. doi: 10.1186/s12936-016-1675-x. Review. Erratum in: Malar J. 2017 Apr 18;16(1):151.

13.

A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.

McCarthy JS, Rückle T, Djeriou E, Cantalloube C, Ter-Minassian D, Baker M, O'Rourke P, Griffin P, Marquart L, Hooft van Huijsduijnen R, Möhrle JJ.

Malar J. 2016 Sep 13;15:469. doi: 10.1186/s12936-016-1511-3.

14.

Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.

McCarthy JS, Baker M, O'Rourke P, Marquart L, Griffin P, Hooft van Huijsduijnen R, Möhrle JJ.

J Antimicrob Chemother. 2016 Sep;71(9):2620-7. doi: 10.1093/jac/dkw174. Epub 2016 Jun 5.

15.

Defining the Effectiveness of Antimalarial Chemotherapy: Investigation of the Lag in Parasite Clearance Following Drug Administration.

Khoury DS, Cromer D, Möhrle JJ, McCarthy JS, Davenport MP.

J Infect Dis. 2016 Sep 1;214(5):753-61. doi: 10.1093/infdis/jiw234. Epub 2016 May 31.

16.

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects.

Krause A, Dingemanse J, Mathis A, Marquart L, Möhrle JJ, McCarthy JS.

Br J Clin Pharmacol. 2016 Aug;82(2):412-21. doi: 10.1111/bcp.12962. Epub 2016 May 11.

17.

Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia.

Pasay CJ, Rockett R, Sekuloski S, Griffin P, Marquart L, Peatey C, Wang CY, O'Rourke P, Elliott S, Baker M, Möhrle JJ, McCarthy JS.

J Infect Dis. 2016 Jul 1;214(1):105-13. doi: 10.1093/infdis/jiw128. Epub 2016 Apr 7.

18.

Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.

McCarthy JS, Marquart L, Sekuloski S, Trenholme K, Elliott S, Griffin P, Rockett R, O'Rourke P, Sloots T, Angulo-Barturen I, Ferrer S, Jiménez-Díaz MB, Martínez MS, Hooft van Huijsduijnen R, Duparc S, Leroy D, Wells TN, Baker M, Möhrle JJ.

Antimicrob Agents Chemother. 2016 May 23;60(6):3669-75. doi: 10.1128/AAC.02883-15. Print 2016 Jun.

19.

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.

Phyo AP, Jittamala P, Nosten FH, Pukrittayakamee S, Imwong M, White NJ, Duparc S, Macintyre F, Baker M, Möhrle JJ.

Lancet Infect Dis. 2016 Jan;16(1):61-69. doi: 10.1016/S1473-3099(15)00320-5. Epub 2015 Oct 5.

20.

Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax.

Wirjanata G, Sebayang BF, Chalfein F, Prayoga, Handayuni I, Trianty L, Kenangalem E, Noviyanti R, Campo B, Poespoprodjo JR, Möhrle JJ, Price RN, Marfurt J.

Antimicrob Agents Chemother. 2015 Oct;59(10):6117-24. doi: 10.1128/AAC.00874-15. Epub 2015 Jul 20.

21.

Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects.

Osorio L, Carter N, Arthur P, Bancone G, Gopalan S, Gupta SK, Noedl H, Kochar SK, Kochar DK, Krudsood S, Lacerda MV, Llanos-Cuentas A, Rueangweerayut R, Srinivasan R, Treiber M, Möhrle JJ, Green J.

Am J Trop Med Hyg. 2015 Jan;92(1):22-27. doi: 10.4269/ajtmh.14-0298. Epub 2014 Nov 10.

22.

Repositioning: the fast track to new anti-malarial medicines?

Lotharius J, Gamo-Benito FJ, Angulo-Barturen I, Clark J, Connelly M, Ferrer-Bazaga S, Parkinson T, Viswanath P, Bandodkar B, Rautela N, Bharath S, Duffy S, Avery VM, Möhrle JJ, Guy RK, Wells T.

Malar J. 2014 Apr 14;13:143. doi: 10.1186/1475-2875-13-143.

23.

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.

Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Möhrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L.

Lancet. 2014 Mar 22;383(9922):1049-58. doi: 10.1016/S0140-6736(13)62568-4. Epub 2013 Dec 19.

PMID:
24360369
24.

Designing the next generation of medicines for malaria control and eradication.

Burrows JN, van Huijsduijnen RH, Möhrle JJ, Oeuvray C, Wells TN.

Malar J. 2013 Jun 6;12:187. doi: 10.1186/1475-2875-12-187. Review.

25.

Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.

Miller AK, Harrell E, Ye L, Baptiste-Brown S, Kleim JP, Ohrt C, Duparc S, Möhrle JJ, Webster A, Stinnett S, Hughes A, Griffith S, Beelen AP.

Br J Clin Pharmacol. 2013 Dec;76(6):858-67. doi: 10.1111/bcp.12160.

26.

Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax.

Marfurt J, Chalfein F, Prayoga P, Wabiser F, Wirjanata G, Sebayang B, Piera KA, Wittlin S, Haynes RK, Möhrle JJ, Anstey NM, Kenangalem E, Price RN.

Antimicrob Agents Chemother. 2012 Oct;56(10):5258-63. doi: 10.1128/AAC.00283-12. Epub 2012 Jul 30.

27.
28.

The management of chronic pain in Switzerland: a comparative survey of Swiss medical specialists treating chronic pain.

Wilder-Smith OH, Möhrle JJ, Dolin PJ, Martin NC.

Eur J Pain. 2001;5(3):285-98.

PMID:
11558984
29.

Supplemental Content

Loading ...
Support Center